Antitumor effect of B16 melanoma cells genetically modified with the angiogenesis inhibitor rnasin.

abstract：:The clinical potential of tumor therapies must be evaluated using animal models closely resembling human cancers. We investigated the impact of locally delivered interferon-gamma (IFN-gamma) on primary hepatocarcinoma spontaneously developed by T-SV40 transgenic mice. A single intratumor injection of adenovirus IFN-ga...

journal_title：Cancer gene therapy

authors： Baratin M,Ziol M,Romieu R,Kayibanda M,Gouilleux F,Briand P,Leroy P,Haddada H,Rénia L,Viguier M,Guillet JG

更新日期：2001-03-01 00:00:00

abstract：:Clear cell renal cell carcinoma (ccRCC) is the highest mortality, invasion, and metastasis subtype of renal cell carcinoma. Bone morphogenetic protein (BMP) family has recently emerged as a group of cancer-related proteins in multiple pathogenesis of cancers. Currently, little is known about the prediction role of BMP...

journal_title：Cancer gene therapy

authors： Xiao W,Wang X,Wang T,Xing J

更新日期：2020-05-01 00:00:00

abstract：:We have described three potential adenovirus type 5 (Ad5)-based replication-competent cancer gene therapy vectors named KD1, KD3, and VRX-007. All three vectors overexpress an Ad5 protein named Adenovirus Death Protein (ADP, also named E3-11.6 K protein). ADP is required for efficient lysis of Ad5-infected cells and s...

journal_title：Cancer gene therapy

authors： Toth K,Tarakanova V,Doronin K,Ward P,Kuppuswamy M,Locke JE,Dawson JE,Kim HJ,Wold WS

更新日期：2003-03-01 00:00:00

abstract：:Apoptotic pathways are initiated as a cellular defense mechanism to eliminate adenovirus-infected cells. We have investigated how E1A-induced apoptosis interferes with viral replication in cancer cells. We found that E1B19K alone can efficiently suppress E1A-induced apoptosis in cancer cells. Viruses deleted for both ...

journal_title：Cancer gene therapy

authors： Rao XM,Tseng MT,Zheng X,Dong Y,Jamshidi-Parsian A,Thompson TC,Brenner MK,McMasters KM,Zhou HS

更新日期：2004-09-01 00:00:00

abstract：:Lung cancer is one of the leading causes of death in the world. The underlying cause for lung cancer has been attributed to various factors that include alteration and mutation in the tumor suppressor genes. Restoration of normal function of the tumor suppressor gene is a potential therapeutic strategy. Recent studies...

journal_title：Cancer gene therapy

authors： Ito I,Ji L,Tanaka F,Saito Y,Gopalan B,Branch CD,Xu K,Atkinson EN,Bekele BN,Stephens LC,Minna JD,Roth JA,Ramesh R

更新日期：2004-11-01 00:00:00

abstract：:Lung cancer is the most frequently occurring cancer in the world and causes more deaths in the United States than does colon, breast, and prostate cancer combined. Despite advances in treatment modalities including radiation, surgery, and chemotherapy, the overall survival in lung cancer remains low. The cytokine tumo...

journal_title：Cancer gene therapy

authors： Sanlioglu S,Luleci G,Thomas KW

更新日期：2001-11-01 00:00:00

abstract：:E6AP was originally identified as the ubiquitin-protein ligase involved in human papillomavirus (HPV) E6-mediated p53 degradation and has since been shown to act as an E3 ubiquitin-protein ligase in the ubiquitination of several other protein substrates. To further define E6AP function at the molecular and cellular le...

journal_title：Cancer gene therapy

authors： Kim Y,Cairns MJ,Marouga R,Sun LQ

更新日期：2003-09-01 00:00:00

abstract：:The purpose of this study was to determine the feasibility of cytokine gene delivery to lymphatic tissue using transduced bone marrow-derived cells. MBAE and pBABE retroviral vectors carrying the genes for murine interleukin-4 and the selection marker neomycin phosphotransferase (neo) were used to transduce bone marro...

journal_title：Cancer gene therapy

authors： Fiehn C,Wettschureck N,Krauthoff A,Haas R,Ho AD

更新日期：2000-08-01 00:00:00

abstract：:Melanoma incidence is growing at a faster rate than any other human malignancy. Wild-type (wt) p53 is important in both G(1) and G(2) cell cycle arrest, and cyclin D1 (CD1) is necessary for G(1)-->S progression in melanoma cells. We reported that an adenoviral vector containing wt p53 significantly reduced [(3)H]thymi...

journal_title：Cancer gene therapy

authors： Sauter ER,Takemoto R,Litwin S,Herlyn M

更新日期：2002-10-01 00:00:00

abstract：:Oncolytic herpes simplex virus (oHSV)-1-based vectors selectively replicate in tumor cells causing direct killing, that is, oncolysis, while sparing normal cells. The oHSVs are promising anticancer agents, but their efficacy, when used as single agents, leaves room for improvement. We hypothesized that combining the d...

journal_title：Cancer gene therapy

authors： Passer BJ,Cheema T,Wu S,Wu CL,Rabkin SD,Martuza RL

更新日期：2013-01-01 00:00:00

abstract：:The prognosis of glioblastoma remains poor despite intensive research efforts. Glioblastoma stem cells (GSCs) contribute to tumorigenesis, invasive capacity, and therapy resistance. Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5), a stem cell marker, is involved in the maintenance of GSCs, although ...

journal_title：Cancer gene therapy

authors： Tanigawa S,Fujita M,Moyama C,Ando S,Ii H,Kojima Y,Fujishita T,Aoki M,Takeuchi H,Yamanaka T,Takahashi Y,Hashimoto N,Nakata S

更新日期：2021-01-07 00:00:00

abstract：:Adenoviral technology has been thoroughly evaluated for delivering genetic material to tumor tissue and the surrounding microenvironment. Almost any gene can be cloned into an adenovirus (Ad) vector, which when combined with strong, constitutively active promoters permit up to a million-fold amplification of the trans...

journal_title：Cancer gene therapy

authors： Card PB,Hogg RT,Gil Del Alcazar CR,Gerard RD

更新日期：2012-07-01 00:00:00

abstract：:Use of a recombinant vaccinia virus expressing human interleukin-2 (IL-2) was evaluated for preparation of tumor vaccines. A/J mice were immunized against neuroblastoma (C1300) cells using a preparation of C1300 cells infected/transfected with the recombinant virus, vCF13, expressing IL-2. A second recombinant vaccini...

journal_title：Cancer gene therapy

authors： Qin H,Chatterjee SK

更新日期：1996-05-01 00:00:00

abstract：:Specificity is a prerequisite for systemic gene therapy of hepatocarcinoma. In vitro, the tumor-specific viral death effector Apoptin selectively induces apoptosis in malignant hepatic cells. Intratumoral treatment of xenografted subcutaneous hepatomas with Apoptin results in tumor regression. Here, we report a system...

journal_title：Cancer gene therapy

authors： Peng DJ,Sun J,Wang YZ,Tian J,Zhang YH,Noteborn MH,Qu S

更新日期：2007-01-01 00:00:00

abstract：:One of the challenges of oncolytic virotherapy is the inability to easily track or monitor virus activity during treatment. Here we describe the construction and functional characterization of Ad/hTC-GFP-E1, an oncolytic virus whose transgenes GFP and E1A are both under the control of a synthetic promoter (hTC). This ...

journal_title：Cancer gene therapy

authors： Davis JJ,Wang L,Dong F,Zhang L,Guo W,Teraishi F,Xu K,Ji L,Fang B

更新日期：2006-07-01 00:00:00

abstract：:Replication-competent oncolytic herpes simplex viruses (HSV), modified by deletion of certain viral growth genes, can selectively target malignant cells. The viral growth gene gamma(1)34.5 has significant homology to GADD34 (growth arrest and DNA damage protein 34), which promotes cell cycle arrest and DNA repair in r...

journal_title：Cancer gene therapy

authors： Jarnagin WR,Zager JS,Hezel M,Stanziale SF,Adusumilli PS,Gonen M,Ebright MI,Culliford A,Gusani NJ,Fong Y

更新日期：2006-03-01 00:00:00

abstract：:Mortality due to colorectal cancer (CRC) is high and is associated with the development of liver metastases. Approximately 40% of human CRCs harbor an activating mutation in the KRAS oncogene. Tumor cells with activated KRAS are particularly sensitive to Reovirus T3D, a non-pathogenic oncolytic virus. The efficacy of ...

journal_title：Cancer gene therapy

authors： Smakman N,van der Bilt JD,van den Wollenberg DJ,Hoeben RC,Borel Rinkes IH,Kranenburg O

更新日期：2006-08-01 00:00:00

abstract：:Prostate cancer is one of the most commonly diagnosed cancers and the second leading cause of cancer deaths in Americans. The high mortality rate is mainly attributed to the invasiveness and metastasis of advanced prostate cancer. Targeting the molecules involved in metastasis could be an effective mode of treatment f...

journal_title：Cancer gene therapy

authors： Nalla AK,Gorantla B,Gondi CS,Lakka SS,Rao JS

更新日期：2010-09-01 00:00:00

abstract：:Oncolytic reovirus administration has been well tolerated by cancer patients in clinical trials. However, its anti-cancer efficacy as a monotherapy remains to be augmented. We and others have previously demonstrated the feasibility of producing replication-competent reoviruses expressing a heterologous transgene. Here...

journal_title：Cancer gene therapy

authors： Kemp V,van den Wollenberg DJM,Camps MGM,van Hall T,Kinderman P,Pronk-van Montfoort N,Hoeben RC

更新日期：2019-09-01 00:00:00

abstract：:Developing continuous systemic delivery of endostatin has been a goal of many laboratories. We have employed a method of gene therapy utilizing different viral constructs. Here, we report that a new serotype of adeno-associated viruses, which incorporates canine endostatin, provides dose-dependent transgene expression...

journal_title：Cancer gene therapy

authors： Tjin Tham Sjin RM,Naspinski J,Birsner AE,Li C,Chan R,Lo KM,Gillies S,Zurakowski D,Folkman J,Samulski J,Javaherian K

更新日期：2006-06-01 00:00:00

abstract：:Interleukin-2 (IL-2) and interleukin-12 (IL-12) are crucial cytokines that induce potent antitumor responses in a variety of animal cancer models. Although single gene transfer of either IL-2 or IL-12 exhibits limited antitumor effects, the combination of IL-2 and IL-12 has been shown to induce a stronger antitumor re...

journal_title：Cancer gene therapy

authors： Tanaka M,Saijo Y,Sato G,Suzuki T,Tazawa R,Satoh K,Nukiwa T

更新日期：2000-11-01 00:00:00

abstract：:The targeted expression of transgenes is one of the principal goals of gene therapy, and it is particularly relevant for the treatment of brain tumors. In this study, we examined the effect of the overexpression of human gas1 (growth arrest specific 1) and human p53 cDNAs, both under the transcriptional control of a p...

journal_title：Cancer gene therapy

authors： Benítez JA,Arregui L,Vergara P,Segovia J

更新日期：2007-10-01 00:00:00

abstract：:Multiple myeloma (MM) accounts for 10% of hematological malignant disorders. Its refractory nature indicates the necessity of developing novel therapeutic modalities. Since interleukin 6 (IL-6) is one of the major growth factors for MM cells, we expressed suppressor of cytokine signaling-1 (SOCS-1), one of the blockad...

journal_title：Cancer gene therapy

authors： Yamamoto M,Nishimoto N,Davydova J,Kishimoto T,Curiel DT

更新日期：2006-02-01 00:00:00

abstract：:Multicomponent lipoplexes have recently emerged as especially promising transfection candidates, as they are from 10 to 100 times more efficient than binary complexes usually employed for gene delivery purposes. Previously, we investigated a number of chemical-physical properties of DNA-lipid complexes that were propo...

journal_title：Cancer gene therapy

authors： Marchini C,Pozzi D,Montani M,Alfonsi C,Amici A,Candeloro De Sanctis S,Digman MA,Sanchez S,Gratton E,Amenitsch H,Fabbretti A,Gualerzi CO,Caracciolo G

更新日期：2011-08-01 00:00:00

abstract：:It has been demonstrated that survivin, a novel member of the inhibitor of apoptosis (IAP) protein family, is expressed in human cancers but is undetectable in normal differentiated tissues. We employed a recombinant adenoviral vector (reAdGL3BSurvivin) in which a tumor-specific survivin promoter and a luciferase repo...

journal_title：Cancer gene therapy

authors： Zhu ZB,Makhija SK,Lu B,Wang M,Kaliberova L,Liu B,Rivera AA,Nettelbeck DM,Mahasreshti PJ,Leath CA,Barker S,Yamaoto M,Li F,Alvarez RD,Curiel DT

更新日期：2004-04-01 00:00:00

abstract：:Immune-isolation of nonautologous cells with microencapsulation protects these cells from graft rejection, thus allowing the same recombinant therapeutic cell line to be implanted in different recipients. This approach was successful in treating HER2/neu-expressing tumors in mice by delivering an interleukin-2 fusion ...

journal_title：Cancer gene therapy

authors： Cirone P,Shen F,Chang PL

更新日期：2005-04-01 00:00:00

abstract：:A phase l study using intravesical Ad-IFNαSyn3 for patients with bacillus Calmette-Guérin-resistant superficial bladder cancer showed a complete remission (CR) of 43% at 90 days after treatment with high levels of interferon-α (IFNα) being produced. Ad-IFNα kills bladder cancer cells by two apoptotic and one necrotic ...

journal_title：Cancer gene therapy

authors： Benedict WF,Fisher M,Zhang XQ,Yang Z,Munsell MF,Dinney CN

更新日期：2014-03-01 00:00:00

abstract：:Cationic liposomes have been shown to potentiate markedly the ability of plasmid DNA to activate innate immune responses. We reasoned therefore that liposome-DNA complexes (LDC) could be used to produce more effective plasmid DNA vaccines for cancer. To test this hypothesis, tumor-bearing mice were vaccinated with con...

journal_title：Cancer gene therapy

authors： U'Ren L,Kedl R,Dow S

更新日期：2006-11-01 00:00:00

abstract：:Melanoma is a common lethal skin cancer. Dissecting molecular mechanisms driving the malignancy of melanoma may uncover potential therapeutic targets. We previously identified miR-145-5p as an important tumor-suppressive microRNA in melanoma. Here, we further investigated the roles of long non-coding RNAs (lncRNAs) in...

journal_title：Cancer gene therapy

authors： Chen XJ,Liu S,Han DM,Han DZ,Sun WJ,Zhao XC

更新日期：2020-12-14 00:00:00

abstract：:Inflammation, among environmental risk factors, is one of the most important contributors to colorectal cancer (CRC) development. In this way, studies revealed that the incidence of CRC in inflammatory bowel disease patients is up to 60% higher than the general population. MicroRNAs (miRNAs), small noncoding RNA molec...

journal_title：Cancer gene therapy

authors： Karimzadeh MR,Zarin M,Ehtesham N,Khosravi S,Soosanabadi M,Mosallaei M,Pourdavoud P

更新日期：2020-11-01 00:00:00